Antioxidants and polyunsaturated fatty acids in multiple sclerosis

Meeteren, M.E. van; Teunissen, C.E.; Dijkstra, C.D.; Tol, Eric A.F. van

doi:10.1038/sj.ejcn.1602255

Cited by 88 publications

(39 citation statements)

References 183 publications

(203 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ghadirian et al [9] in a casecontrol study found inverse association between vegetable protein, dietary fiber, vitamin C (high loaded in factor 4), thiamin, riboflavin (loaded in factor 2), calcium (high loaded in factor 2) and potassium and MS. These factors may prevent MS by antioxidant activity and radical scavenging or regulating process of nervous system [9,28]. Unlike the suggested roles, no associations between carotenoids (loaded in factor 4), vitamin C (loaded in factor 4), and vitamin E and MS were found in NHS and NHS II cohorts studies [29].…”

Section: Discussionmentioning

confidence: 80%

Nutrient Patterns and Risk of Multiple Sclerosis: A Case-Control Study

Akhoondan

2014

J Neurol Res

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 80%

Nutrient Patterns and Risk of Multiple Sclerosis: A Case-Control Study

Akhoondan

2014

J Neurol Res

View full text Add to dashboard Cite

show abstract

“…In the pathogenesis of MS, oxidative stress is important (16). In GEMSP, the presence of vitamins and certain amino acids and their derivatives (alpha-tocopherol-succinate, ascorbic acid, taurine and 5-methoxy-tryptamine) are important neuroprotective components and radical scavengers, exerting a crucial role against nitrosative and oxidative stress (1,11).…”

Section: Discussionmentioning

confidence: 99%

Follow-up of multiple sclerosis patients treated with Endotherapia (GEMSP)

Geffard¹,

Mangas²,

Coveñas

2017

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Endotherapia (GEMSP) is a novel therapeutic approach for multiple sclerosis (MS). The aim of the present study was to demonstrate the efficiency of Endotherapia in the follow-up of 193 patients with MS. The efficiency coefficient that was evaluated was the Expanded Disability Status Scale (EDSS) score, which is a functional scale of MS progression. The evaluated score of each patient during follow-up visits was compared with the theoretical score of the disease progression without GEMSP. The evolution of the EDSS score was evaluated according to the inclusion score. The quantitative global study of the EDSS score highlighted a statistically significant difference between the final average scores of the treatment with GEMSP (M) and worldwide reference (R) groups. The improvement of the M group compared with the R group was 24.5%. According to the final EDSS scores, the study highlighted a difference in favor of the M group with 62.0% for scores ≤3, 7.8% for scores between 3 and 6 and 19.6% for scores ≥6. According to the qualitative evolution of the EDSS scores, the improvements in favor of group M were 49.3% for scores ≤3, 79.1% for scores between 3 and 6 and 19.5% for scores ≥6. The qualitative study of the EDSS score showed a statistically significant success percentage; the success percentages were between 59.1 and 90.0%. In a larger population of MS patients, the data confirm the beneficial effects of GEMSP that were previously reported in pre-clinical and clinical studies. In addition, 78% of patients showed an improvement or deceleration of the disease.

show abstract

“…Increased levels of the indicators of OS and/or decreased levels of antioxidant enzymes and antioxidants have been detected in the blood and cerebrospinal fluid of MS patients in the active phases of the disease; these findings indicate that increased levels of ROS may cause the depletion of cellular antioxidants [van der Goes et al, 1998;van Horssen et al, 2010;van Meeteren et al, 2005]. In recent decades, immunologic cascade and inflammation have been proposed as causative factors of neurological diseases and autoimmune disorders, such as MS [Taupin, 2008].…”

Section: Inflammation and Immunopathogenesis Of Ros And No In Msmentioning

confidence: 99%